Cortexin
A Russian brain-extract powder run in 10-day courses after a stroke, concussion or burnout. Long clinical history, little Western proof.
What it is
Cortexin is for the weeks after something knocked the brain off course: a stroke, a concussion that left fog, a long illness that took your sharpness with it. It is a 10-day course of daily shots, and the realistic hope is a gentler, slightly faster climb back, not a buzz.
Who runs it: people in the first months after a stroke or head injury, people whose thinking never fully came back after a bad flu or a burnout year, and families in Russia and Eastern Europe, where it has been a pediatric and neurology prescription for decades. A smaller group of biohackers runs a course for 'brain maintenance'. The research is about the first groups; the last group is extrapolating.
What it is: not one peptide but a filtered extract of cow or pig brain cortex, the small (under 10 kDa) peptide fraction, freeze-dried into a powder. The idea is that cortex-derived regulatory peptides act on cortex with some tissue specificity, supporting growth-factor signaling (BDNF and relatives), the glutamate-GABA balance, and resistance to oxidative stress. It is a sibling of Cerebrolysin, which is the liquid version of the same idea with more Western-language trials.
How it is run and what you would notice: the clinical dose is 10 mg once a day for 10 days, intramuscular in the clinic, subQ in the community; 5 mg is the cautious first course. A 20 mg vial is two doses, so a full course is five vials. Nothing happens on day one. The reports cluster in the second week and the two weeks after: clearer mornings, steadier mood, better sleep, easier words. Then usually a few months off before the next course, not because it stops working but because the effect is meant to carry on after the course ends; repeat when the benefit fades. The mistake is running it like a daily nootropic; it is a course drug, and stacking courses back to back has no support and doubles the animal-protein exposure.
The evidence, once: dozens of Russian clinical studies in stroke recovery, encephalopathy, head injury and pediatric neurology, which is more human data than most research peptides have. Nearly all of it is Russian-language, open-label or small, and none has been replicated to Western trial standards. It is registered as a medicine in Russia and nowhere in the West. Read it as plausible and under-verified.
When it is not worth it: a healthy brain that wants focus (Semax works the same day and costs far less), or a real neurological condition you are trying to self-treat (that is a specialist's job, and the course should sit inside their plan). If you want the same category with more published trials, Cerebrolysin is the better-documented sibling; if you want the bioregulator approach to the brain, Pinealon is cheaper and gentler.
What people use it for
Brain cell survival and repair
Some evidenceIn cell and animal work, Cortexin fractions support BDNF-type growth-factor signaling and help neurons survive and re-wire after injury. This is the mechanism the whole product rests on. It is shown in models, not measured in people, so it tells you why it might work, not that it does.
Recovery after a stroke
Some evidenceMultiple Russian clinical studies report faster functional and cognitive recovery when Cortexin courses are added to standard stroke care. They are mostly open-label or small, and none has been repeated under Western trial conditions. For someone in rehab it is a reasonable add-on; it is not a treatment on its own.
Fog after illness, burnout or concussion
Some evidenceThe 'encephalopathy' studies, Russian shorthand for diffuse brain under-performance from poor blood flow, toxins or injury, report clearer thinking and better mood after a course. The same caveats apply, and this is the use most community runs are really chasing. Expect subtle, not dramatic.
Protection during injury
Early daysIn animal models of ischemia and trauma, Cortexin reduced oxidative damage and improved the glutamate-GABA balance. This supports the clinical claims mechanically but has not been tested as a protective course in people before an event.
How people use it
Safety, in brief
Things people sometimes notice
- Soreness at the injection site; the clinical 10 mg dose is a full 1 mL
- A headache or restlessness in the first few days for some people
- Vivid dreams or lighter sleep early in the course, which usually settles
The full picture — stop signs and who should talk to a doctor first — is on the dosing guide.
Sources
The labels and studies behind this page. Each link opens the original on PubMed, DailyMed or ClinicalTrials.gov.
- Cortexin® Ameliorates High Glucose-Induced Neuropathy in Cultured Rat Sensory Neurons
- Efficacy of cortexin in acute and recovery periodes of hemispheric ischemic stroke
- Dose-dependent effects of cortexin in chronic cerebral ischemia (results of a multicenter randomized controlled study)
- Antioxidant effect of cortexin, cerebrolysin and actovegin in rats with chronic cerebrovascular insufficiency